Compare

Selank vs Semaglutide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Selank

596 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 50% · Mixed 34% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
-141
Energy
-75
Mood
1
Focus
-102
Sleep quality
-48

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
-45
Dizziness
4
Fatigue
-34
Nausea
-107
Water retention
-48

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 100–200 mcg

Reports span 25–1000 mcg

25–50
7
50–100
11
100–200
21
200–400
15
400–600
9
600–1000
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing40stacking28side effects16selank29

How repeat users are trending

Among repeat reporters, 60% said they felt similar to their last entry, 42% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 25 days · Based on 131 repeat reporters

Semaglutide

304 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 58% · Mixed 30% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
67
Recovery
108
Digestive comfort
159
Skin appearance
165
Appetite control
76

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
163
Anxiety
188
Flushing
124
Headache
161
GI discomfort
75

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
4
50–100
14
100–200
18
200–400
9
400–600
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing28stacking16side effects24semaglutide12

How repeat users are trending

Among repeat reporters, 53% said they felt similar to their last entry, 44% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 67 repeat reporters

Sources (18)

Published sources linked on the Selank and Semaglutide wiki pages.

  1. PubMed

    Selank and short peptides regulate expression of inflammatory genes

    Ershov FI, Uchakin PN, Ershova OV. Bull Exp Biol Med. 2017

    Source
    Wiki study page →
  2. PubMed

    Selank, a tuftsin analogue, demonstrates anxiolytic activity

    Seredenin SB, Kozlovskaya MM. Bull Exp Biol Med. 2008

    Source
    Wiki study page →
  3. PubMed

    Functional Connectomic Approach to Studying Selank and Semax Effects

    Panikratova YR, Lebedeva IS, Sokolov OY, et al. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020

    Source
    Wiki study page →
  4. PubMed

    Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats

    Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bulletin of experimental biology and medicine. 2022

    Source
    Wiki study page →
  5. FDA Drug Label

    WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information

    Novo Nordisk. FDA Drug Label. 2021

    Source
    Wiki study page →
  6. FDA Drug Label

    OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information

    Novo Nordisk. FDA Drug Label. 2017

    Source
    Wiki study page →
  7. PubMed

    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Semaglutide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    Once-Weekly Semaglutide in Adolescents with Obesity.

    Weghuber D, Barrett T, Barrientos-Pérez M, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  10. PubMed

    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

    Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. N Engl J Med. 2023

    Source
    Wiki study page →
  11. PubMed

    Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

    Wharton S, Calanna S, Davies M, et al. Diabetes Obes Metab. 2022

    Source
    Wiki study page →
  12. PubMed

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine. 2023

    Source
    Wiki study page →
  13. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  14. PubMed

    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    Wadden TA, Bailey TS, Billings LK, et al. JAMA. 2021

    Source
    Wiki study page →
  15. PubMed

    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Wilding JPH, Batterham RL, Calanna S, et al. Diabetes Obes Metab. 2022

    Source
    Wiki study page →
  16. PubMed

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6)

    Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016

    Source
    Wiki study page →